Aurélie Ferru

1.4k total citations
30 papers, 439 citations indexed

About

Aurélie Ferru is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Aurélie Ferru has authored 30 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in Aurélie Ferru's work include Colorectal Cancer Treatments and Studies (11 papers), Genetic factors in colorectal cancer (5 papers) and Cancer Treatment and Pharmacology (5 papers). Aurélie Ferru is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Genetic factors in colorectal cancer (5 papers) and Cancer Treatment and Pharmacology (5 papers). Aurélie Ferru collaborates with scholars based in France and United States. Aurélie Ferru's co-authors include L. Karayan-Tapon, Thierry Lecomte, David Tougeron, Christine Silvain, Claire Villalva, P. Levillain, Jean‐Christophe Pagès, Christine Collin, Martin Schlumberger and Isabelle Borget and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Aurélie Ferru

27 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aurélie Ferru France	11	250	106	93	86	84	30	439
Bhumsuk Keam South Korea	9	312 1.2×	247 2.3×	98 1.1×	56 0.7×	72 0.9×	17	568
Hiroki Ikezawa Japan	11	300 1.2×	110 1.0×	77 0.8×	60 0.7×	107 1.3×	32	512
Ann W. Gramza United States	10	200 0.8×	206 1.9×	137 1.5×	52 0.6×	37 0.4×	22	552
Kartik Viswanathan United States	11	186 0.7×	51 0.5×	109 1.2×	74 0.9×	57 0.7×	28	423
Rieke Fischer Germany	9	503 2.0×	79 0.7×	60 0.6×	122 1.4×	75 0.9×	33	675
Shonan Sho United States	11	254 1.0×	73 0.7×	93 1.0×	166 1.9×	32 0.4×	16	443
Carrie B. Marshall United States	11	140 0.6×	81 0.8×	94 1.0×	69 0.8×	26 0.3×	20	397
Neda Stjepanovic Spain	13	207 0.8×	44 0.4×	155 1.7×	118 1.4×	150 1.8×	30	573
Yoshinori Hirashima Japan	13	335 1.3×	48 0.5×	155 1.7×	65 0.8×	42 0.5×	29	572
Pradeep Thanigaimani United States	7	503 2.0×	129 1.2×	71 0.8×	56 0.7×	68 0.8×	11	669

Countries citing papers authored by Aurélie Ferru

Since Specialization

Citations

This map shows the geographic impact of Aurélie Ferru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélie Ferru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélie Ferru more than expected).

Fields of papers citing papers by Aurélie Ferru

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurélie Ferru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélie Ferru. The network helps show where Aurélie Ferru may publish in the future.

Co-authorship network of co-authors of Aurélie Ferru

This figure shows the co-authorship network connecting the top 25 collaborators of Aurélie Ferru. A scholar is included among the top collaborators of Aurélie Ferru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurélie Ferru. Aurélie Ferru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Randrian, Violaine, Camille Evrard, Claire Boyer, et al.. (2025). COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA prospective study. BMC Cancer. 25(1). 398–398.

Evrard, Camille, et al.. (2025). Prognostic and Predictive Value of Microsatellite Instability Analysis in Circulating Tumor DNA Using Digital Droplet PCR for Patients With Microsatellite Instability Colorectal Cancers. Laboratory Investigation. 105(8). 104176–104176.

Caulet, Morgane, Olivier Bouché, Christophe Borg, et al.. (2024). Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer. Digestive and Liver Disease. 57(1). 141–148. 1 indexed citations

Tasu, Jean‐Pierre, Guillaume Herpe, Michel Carretier, et al.. (2024). Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study. European Radiology. 34(10). 6885–6895. 1 indexed citations

Caulet, Morgane, Gilles Paintaud, Nicolas Azzopardi, et al.. (2023). Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients. British Journal of Clinical Pharmacology. 90(4). 976–986. 1 indexed citations

Evrard, Camille, Pierre Ingrand, Gaëlle Tachon, et al.. (2023). Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study. Digestive and Liver Disease. 55(11). 1562–1572. 7 indexed citations

Baudin, Éric, Hélène Senellart, Nadia Bouarioua, et al.. (2021). Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors. Neuroendocrinology. 112(6). 537–546. 15 indexed citations

Girard, Nicolas, Julien Mazières, Josiane Otto, et al.. (2021). LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). Annals of Oncology. 32. S1318–S1318. 19 indexed citations

Ingrand, Isabelle, Gautier Défossez, Claire Lafay‐Chebassier, et al.. (2019). Serious adverse effects occurring after chemotherapy: A general cancer registry‐based incidence survey. British Journal of Clinical Pharmacology. 86(4). 711–722. 21 indexed citations

10.

Ferru, Aurélie, et al.. (2018). Management of venous thromboembolism in cancer patients according to guidelines after educative measures. Bulletin du Cancer. 105(5). 486–492. 2 indexed citations

11.

Ferru, Aurélie, et al.. (2018). Thrombose et cancer : sensibilisation des professionnels de santé libéraux et des patients en région Poitou-Charentes. JMV-Journal de Médecine Vasculaire. 43(3). 182–192.

12.

Berdelou, A., Isabelle Borget, Yann Godbert, et al.. (2017). Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. Thyroid. 28(1). 72–78. 102 indexed citations

13.

Tougeron, David, Romain Cohen, David Sefrioui, et al.. (2017). A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. Annals of Oncology. 28. v180–v180. 10 indexed citations

14.

Colin, Olivier, et al.. (2017). Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database. Fundamental and Clinical Pharmacology. 32(2). 227–233. 2 indexed citations

15.

Tougeron, David, Thierry Lecomte, Jean‐Christophe Pagès, et al.. (2013). Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Annals of Oncology. 24(5). 1267–1273. 84 indexed citations

16.

Tougeron, David, Ulrich Cortes, Aurélie Ferru, et al.. (2013). Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 72(2). 397–403. 14 indexed citations

17.

Ferru, Aurélie, et al.. (2013). Application des recommandations dans le traitement de la maladie thromboembolique veineuse chez les patients atteints de cancer : étude rétrospective sur 145 cas. Journal des Maladies Vasculaires. 38(3). 185–192. 14 indexed citations

18.

Bourgeois, Hugues, Florence Joly, Éric Pujade-Lauraine, et al.. (2006). Phase I Study of Pegylated Liposomal Doxorubicin in Combination With Ifosfamide in Pretreated Ovarian Cancer Patients. American Journal of Clinical Oncology. 29(4). 399–404. 9 indexed citations

19.

Bourgeois, Hugues, Aurélie Ferru, Alain Lortholary, et al.. (2006). Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer. American Journal of Clinical Oncology. 29(3). 267–275. 10 indexed citations

20.

Ferru, Aurélie, Stéphanie Denis, Joëlle Guilhot, et al.. (2005). Expression of TAp73 and ΔNp73 isoform transcripts in thyroid tumours. European Journal of Surgical Oncology. 32(2). 228–230. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact